RPRX
I posted this on the RPRX board too, but for those of you who don't read it....
This is funny. I've pasted below the Reuters report on the recent news that appeared in my E*Trade account. Now, if you read this and didn't know better (a category under which the majority of retail falls) wouldn't you think this was bad news? Especially the headline.
Might be a brief selloff tomorrow morning before the real news sinks in, depending on how many people read only this.
Whoever writes biotech news at Reuters should be shot. Or do they have a computer program writing this kind of stuff? I know they do for earnings releases.
Repros to revise testosterone drug trial design
Reuters - October 15, 2007 8:25 PM ET
NEW YORK, Oct 15 (Reuters) - Repros Therapeutics Inc (RPRX) said on Monday it plans to submit a revised protocol for future clinical trials of its experimental drug Androxal to treat testosterone deficiency, following discussions with U.S. health regulators.
"We believe Androxal may have the potential to reach a broader spectrum of endocrinological dysfunctions beyond the effects of low testosterone alone," said Chief Executive Joseph Podolski. (Reporting by Martinne Geller)
